Since KRAS/NRAS/BRAF genes are involved in the MAPK pathway, the use of MAPK inhibitors in combination with immunomodulatory drugs in MM patients with mutations in these genes is being discussed [9]. The gene discussed is KRAS; the disease is Miyoshi myopathy.